Bingo—you’ve got one of the two trial-design wrinkles: the “8+16” arm in the phase-3 ADVANCE trial (#msg-27623529). In this trial arm, patients receive only 8 weeks of Telaprevir + SoC followed by 16 weeks of SoC alone rather than the usual “12+12.” Clearly, the shorter duration of Telaprevir lessens the chances of a consequential Telaprevir-induced rash.
Now all you need to fully solve the quiz is the second trial-design wrinkle to reduce the impact of rash in the phase-3 Telaprevir program.
Market Data 
Markets 
AI
